Xyence sells its stake in AnaBios Corporation 

07 June 2022 - Xyence Capital SGR S.p.A. ("Xyence") sold its stake (22,8%) in AnaBios Corporation - US Contract Research Organization ("CRO") active in drug development and translational research services - to Ampersand Capital Partners (“Ampersand”), a private equity firm specializing in growth equity investments in the life sciences and healthcare sectors.

Xyence Capital invested in Anabios since 2016, helping the company to grow by accelerating the innovation and development of Phase X® technology, an unprecedented technology that provides the opportunity to de-risk drug development programs. Anabios represents for Xyence a successfully completed investment in the extremely competitive US Market.